NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis $6.86 +0.37 (+5.70%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$6.86 +0.00 (+0.07%) As of 08/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Enanta Pharmaceuticals Stock (NASDAQ:ENTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enanta Pharmaceuticals alerts:Sign Up Key Stats Today's Range$6.54▼$7.7350-Day Range$6.49▼$8.1052-Week Range$4.09▼$13.43Volume225,273 shsAverage Volume176,921 shsMarket Capitalization$146.67 millionP/E RatioN/ADividend YieldN/APrice Target$21.67Consensus RatingBuy Company Overview Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Read More Enanta Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreENTA MarketRank™: Enanta Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 261st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Enanta Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($4.65) to ($4.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.39% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently increased by 1.65%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-1.11 Percentage of Shares Shorted12.39% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently increased by 1.65%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.63 News SentimentEnanta Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest2 people have searched for ENTA on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.89% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enanta Pharmaceuticals' insider trading history. Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Stock News HeadlinesEnanta price target raised to $25 from $24 at Citizens JMPAugust 13 at 2:57 AM | msn.comEnanta Pharmaceuticals: Fiscal Q3 Earnings SnapshotAugust 11 at 10:38 PM | sfgate.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 13 at 2:00 AM | Porter & Company (Ad)Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025August 11 at 4:02 PM | businesswire.comOne Enanta Pharmaceuticals Insider Raised Their Stake In The Previous YearJuly 26, 2025 | finance.yahoo.comEnanta Pharmaceuticals to Participate in Baird’s Biotech Discovery SeriesJuly 16, 2025 | finance.yahoo.comEnanta Pharmaceuticals to Participate in Baird's Biotech Discovery SeriesJuly 15, 2025 | businesswire.comEnanta Pharmaceuticals, Inc. (ENTA) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comSee More Headlines ENTA Stock Analysis - Frequently Asked Questions How have ENTA shares performed this year? Enanta Pharmaceuticals' stock was trading at $5.75 at the beginning of the year. Since then, ENTA stock has increased by 19.3% and is now trading at $6.86. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its earnings results on Monday, August, 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.25) by $0.40. The biotechnology company had revenue of $18.31 million for the quarter, compared to analysts' expectations of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative trailing twelve-month return on equity of 82.60%. Who are Enanta Pharmaceuticals' major shareholders? Top institutional shareholders of Enanta Pharmaceuticals include Geode Capital Management LLC (2.27%), JPMorgan Chase & Co. (0.61%), Assenagon Asset Management S.A. (0.50%) and Bank of Montreal Can (0.16%). Insiders that own company stock include Jay R Luly, Yat Sun Or, Paul J Mellett, Brendan Luu, Tara Lynn Kieffer, Scott T Rottinghaus and Terry Vance. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG). Company Calendar Last Earnings8/11/2025Today8/13/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTA CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees160Year FoundedN/APrice Target and Rating Average Price Target for Enanta Pharmaceuticals$21.67 High Price Target$25.00 Low Price Target$20.00 Potential Upside/Downside+215.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($4.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$116.04 million Net Margins-141.98% Pretax Margin-153.41% Return on Equity-82.60% Return on Assets-26.33% Debt Debt-to-Equity RatioN/A Current Ratio5.29 Quick Ratio5.29 Sales & Book Value Annual Sales$67.64 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$6.08 per share Price / Book1.13Miscellaneous Outstanding Shares21,380,000Free Float18,408,000Market Cap$146.67 million OptionableOptionable Beta0.88 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:ENTA) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.